Edition:
United Kingdom

Allergan plc (AGN.N)

AGN.N on New York Stock Exchange

222.97USD
21 Aug 2017
Change (% chg)

$-1.02 (-0.46%)
Prev Close
$223.99
Open
$223.88
Day's High
$225.13
Day's Low
$222.41
Volume
817,517
Avg. Vol
498,432
52-wk High
$256.78
52-wk Low
$184.58

Select another date:

Wed, Aug 9 2017

BRIEF-Allergan says as part of internal optimization restructuring programs, co intends to eliminate about 400 positions - SEC Filing‍​

* Allergan Plc - As part of internal optimization restructuring programs, co intends to eliminate about 400 positions - Sec Filing‍​

BRIEF-FDA approves Medicines360's SNDA for Liletta to prevent pregnancy for up to four years

* FDA approves Medicines360's SNDA for Liletta (levonorgestrel-releasing intrauterine system) 52 mg to prevent pregnancy for up to four years

BRIEF-Allergan Plc Q2 revenue $4.0 billion

* Allergan reports continued strong execution in second quarter 2017 with 9% increase in GAAP net revenues to $4.0 billion

Botox-maker Allergan's quarterly profit beats estimates

Botox-maker Allergan Plc reported a better-than-expected quarterly profit, helped by strength in its medical aesthetics unit, prompting the drugmaker to raise its full-year revenue forecast.

UPDATE 1-Botox-maker Allergan's quarterly profit beats estimates

Aug 3 Botox-maker Allergan Plc reported a better-than-expected quarterly profit, helped by strength in its medical aesthetics unit, prompting the drugmaker to raise its full-year revenue forecast.

Botox-maker Allergan quarterly revenue rises 9 pct

Aug 3 Drugmaker Allergan Plc posted a 9 percent rise in quarterly revenue, helped by strength in its medical aesthetics unit.

BRIEF-Allergan Q3 cash dividend of $0.70/shr

* Allergan announces third quarter 2017 cash dividend of $0.70 per ordinary share Source text for Eikon: Further company coverage:

BRIEF-Amgen and Allergan submit biosimilar Biologics License application for ABP 980 to U.S. FDA

* Amgen and Allergan submit biosimilar Biologics License Application for ABP 980 to US Food and Drug Administration

BRIEF-U.S. Senator Claire McCaskill opioid investigation expands to include distributors and additional manufacturers‍​

* U.S. Senator Claire McCaskill opioid investigation expands to include distributors and additional manufacturers‍​

BRIEF-Allergan submits investigational NDA for rtgel in combination with botox

* Investigational new drug application for rtgel™ in combination with botox® for the treatment of overactive bladder submitted to FDA by Allergan

Select another date: